Results 281 to 290 of about 457,600 (353)

Disrupting CSPG‐Driven Microglia–Astrocyte Crosstalk Enables Scar‐Free Repair in Spinal Cord Injury

Advanced Science, EarlyView.
This study identifies CSPGs as key drivers of glial scar maturation after spinal cord injury by reprogramming microglial metabolism and inducing astrocyte fibrosis. To address this, a reactive oxygen species‐responsive, reactive astrocyte‐targeted ChABC gene delivery system is designed to locally degrade CSPGs, precisely disrupt maladaptive glial ...
Yufei Zheng, Zhaowei Zhang, Zezhou Fu, Qingqing Wang, Siwen Zhang, Tingyu Zhang, Meifei Zhu, Shunwu Fan, Youqing Shen, Jiajia Xiang, Xin Liu   +10 more
wiley   +1 more source

BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based on the FAERS database with a case report. [PDF]

BMC Nephrol
Shi Y, Deng L, Zhu J, Huang Y, Zeng M, Mao H, Huang Z, Wu B.   +7 more
europepmc   +1 more source

Repurposing of Chemokine Antagonists for Combined Phase‐Resolved Spinal Cord Injury Treatment

Advanced Science, EarlyView.
Spinal cord injury (SCI) in mammals is accompanied by a massive cytokine storm in cerebrospinal fluid, mainly driven by CXCL1, IL‐6, and CCL2‐5. Sub‐acute phase is mostly associated with IL‐2, IL‐7, CCL22, and CX3CL1, whereas TNFα and IL17α permanently persists in CNS even weeks following SCI.
Alexey A. Belogurov Jr., Georgii B. Telegin, Aleksandr S. Chernov, Anna A. Kudriaeva, Alexey N. Minakov, Maksim V. Rodionov, Vitaly A. Kazakov, Viktor A. Palikov, Yuri M. Poluektov, Rustam H. Ziganshin, Daria A. Orlova, Alena S. Evpak, Daniil A. Barsuk, Fedor A. Mesheryakov, Aldo Spallone, Dmitry S. Asyutin, Igor N. Pronin, Nikolay A. Konovalov, Dmitri Yu Usachev, Alexander G. Gabibov, Alexander N. Konovalov   +20 more
wiley   +1 more source

MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis. [PDF]

BMC Cancer
Hu D, Hu Y, Lei S, Wu D, Wang Y.
europepmc   +1 more source

SLPI⁺ AT2‐Like Cells Orchestrate Lung Adenocarcinoma Invasion via Wnt Pathway Activation and Stromal Crosstalk in a Spatially Defined Margin Niche

Advanced Science, EarlyView.
Integrating spatial transcriptomics and single‐cell RNA sequencing, this study identifies a novel subpopulation of SLPI⁺ AT2‐like cells at the invasive margin of lung adenocarcinoma (LUAD). These cells, through stromal crosstalk and Wnt pathway activation, promote tumor stemness and invasion.
Zhoufeng Wang, Guonian Zhu, Pan Tang, Yan Wang, Wenxin Luo, Wenpeng Song, Zhikang Pan, Bingjie Zheng, YongChao Jiang, Defu Xiao, Xin Jin, Yong Bai, Guowei Che, Weimin Li   +13 more
wiley   +1 more source

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. [PDF]

Med Sci (Basel)
Shalata W, Naamneh R, Najjar W, Abu Amna M, Asla M, Agbarya A, Brenner R, Abu Jama A, Abu Yasin N, Abu Juda M, Abu Zeid EED, Rouvinov K, Yakobson A.   +12 more
europepmc   +1 more source

Crossing the Blood–Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy

Advanced Science, EarlyView.
Molecularly imprinted polymeric nanocarriers (nanoMIPs) offer robust, antibody‐mimetic platforms to overcome the blood‐brain barrier. The article surveys nanoMIP design and ligand‐directed surface engineering that harness receptor‐mediated transcytosis, and highlights therapeutic and diagnostic applications in neurodegeneration, brain tumors and ...
Ranjit De, Shuliang Shi, Kyong‐Tai Kim
wiley   +1 more source

The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair. [PDF]

Int Wound J
Nahm WJ, Falanga V.
europepmc   +1 more source

Integrin β3 Orchestrates Hepatic Steatosis via a Novel CD36‐Dependent Lipid Uptake Complex

Advanced Science, EarlyView.
In MASH, ITGB3 recruits LYN and drives its ubiquitin‐proteasomal degradation via phosphorylation. This relieves DHHC5 inhibition, enabling ITGB3/DHHC5/CD36 complex assembly to enhance CD36 palmitoylation and fatty acid uptake, thereby exacerbating disease. Targeting ITGB3 blocks this pathogenic axis and ameliorates MASH.
Ying Zhang, Lei Dai, Zhongquan Cui, Ye Zhou, Wenyuan Dong, Hongcheng Jiang, Mengwen Wang, Xiaodan Zhong, Wei Dong, Zhang Yue, Thati Madhusudhan, Hongjie Wang, Xiong Zhong Ruan, Hesong Zeng   +13 more
wiley   +1 more source

Case Report: Management of a <i>BCR-ABL1</i>-positive high-risk rhabdomyosarcoma patient using tyrosine kinase inhibitors. [PDF]

Front Med (Lausanne)
Li F, Jiang D, Liu Y, Yin M, Zhong Y, Xu M, Zhang A, Han Y.   +7 more
europepmc   +1 more source